Compare IGC & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGC | ICMB |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 30.7M |
| IPO Year | 2005 | 2013 |
| Metric | IGC | ICMB |
|---|---|---|
| Price | $0.29 | $1.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 466.5K | 41.5K |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 21.74% |
| EPS Growth | ★ 59.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,271,000.00 | N/A |
| Revenue This Year | N/A | $7.43 |
| Revenue Next Year | $13.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $1.28 |
| 52 Week High | $0.50 | $3.12 |
| Indicator | IGC | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 30.70 |
| Support Level | $0.28 | $1.28 |
| Resistance Level | $0.31 | $3.00 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 29.01 | 19.23 |
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.